Tardive dyskinesia is a movement disorder which manifests as repeated uncontrolled jerky or writhing movements of the face and body and is caused by chronic exposure to dopamine receptor-blocking agents (drugs such as some antipsychotics, tricyclic antidepressants and antiemetics). It is estimated that it affects between 20-50% of all patients treated with antipsychotics.
Based on its mechanism of action, pre-clinical and clinical evidence, we are pursuing CP-011 for the treatment of tardive dyskinesia.
Contera Pharma A/S
Agern Allé 24
Thomas Sager, CEO
Jaihong Kwon, CFO
Bukwang Pharmaceutical Co., Ltd. was established on October 17th, 1960 and has since continued to produce excellent medications with the aim of improving global health for the last 55 years.